Overview
- Moderna and Merck said on Aug. 19 that their individualized mRNA neoantigen vaccine, intismeran autogene, given with Merck’s Keytruda met the Phase 3 interim endpoints of recurrence‑free survival and distant metastasis‑free survival in about 1,137 completely resected stage IIB–IV melanoma patients.
- The vaccine is bespoke: each patient’s tumor is sequenced, up to 34 neoantigens are selected by algorithm, and a custom mRNA dose is manufactured, a process that affects timing, cost and logistics.
- Analysts estimate peak sales in the low single‑digit billions by 2032 and comparable personalized therapies suggest a full treatment course could be on the order of $300,000, creating clear pricing and reimbursement pressure in Europe and the U.S.
- Markets reacted with extreme volatility—Moderna shares jumped roughly 177% in one session before correcting—while analysts warned investor enthusiasm may exceed near‑term clinical and commercial realities.
- The trial continues to collect data on overall survival and subgroup effects, full detailed results will be presented at scientific meetings, and experts caution success in melanoma may not translate to tumors with fewer mutations or more immunosuppressive microenvironments.